Pactiv Evergreen-Novolex Deal Gets Regulatory Approvals

, MT Newswires -  4:28 PM ET 3/28/2025 mergers-and-acquisitions

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

04:28 PM EDT, 03/28/2025 (MT Newswires) -- Pactiv Evergreen ( PTVE ) said late Friday that Novolex's proposed acquisition of the company for $18 per share in cash has received all required regulatory approvals.

The deal is now expected to close on Tuesday, the company said.

Pactiv said that upon completion of the deal, it will become a privately held company, and its shares will no longer be listed on Nasdaq.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.